<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Seta, Francesco</style></author><author><style face="normal" font="default" size="100%">Restaino, Stefano</style></author><author><style face="normal" font="default" size="100%">Banco, Rubina</style></author><author><style face="normal" font="default" size="100%">Conversano, Ester</style></author><author><style face="normal" font="default" size="100%">De Leo, Rossella</style></author><author><style face="normal" font="default" size="100%">Tonon, Maddalena</style></author><author><style face="normal" font="default" size="100%">Maso, Gianpaolo</style></author><author><style face="normal" font="default" size="100%">Barbati, Giulia</style></author><author><style face="normal" font="default" size="100%">Lello, Stefano</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of estroprogestins containing natural estrogen on vaginal flora.</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecol Endocrinol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Gynecol. Endocrinol.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style  face="normal" font="default" size="100%">Estradiol</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Megestrol</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Nandrolone</style></keyword><keyword><style  face="normal" font="default" size="100%">Norpregnadienes</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Vagina</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">830-5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Estroprogestins with &quot;natural oestrogen&quot; has represented a new option in terms of combined hormonal contraception. So, the aim of this study is to investigate how estroprogestins with natural estrogen may modify the vaginal niche. In literature, very few studies focused on the interaction between hormonal contraception and vaginal milieu. This is a prospective comparative study. We enrolled 60 women from January 2013 to September 2013, 30 of them were administered estradiol valerate dienogest (E2V+DNG - Klaira®) in a quadriphasic regimen, while the other 30 women were administered 17-β estradiol with nomestrol acetate (EV+NOMAC - Zoely®) in a monophasic regimen. After a baseline study of vaginal milieu at recruitment of patients (Gram stain with Nugent score, vaginal pH, vaginal wet mount for the quantification of leukocytes, Lactobacilli and/or presence of Candida), we performed the same follow-up after six months of estroprogestin therapy. Our results showed that the women treated with E2V+DNG had a trend of an improvement of vaginal health in terms of increase of lactobacillar flora and reduction of vaginal pH in place of women treated with EV+NOMAC that showed a reduction of cervical mucus. Finally, our data about the effects on vaginal flora exerted by two estroprogestin pills (EPs) containing a natural estrogen suggest slight, but interesting differences in terms of vaginal ecology. These differences could be related to the type of estrogen, type of progestin, regimen of administration and, after all, to the net balance between estrogenic and progestin component of the EPs.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/24993504?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sartore, Andrea</style></author><author><style face="normal" font="default" size="100%">De Seta, Francesco</style></author><author><style face="normal" font="default" size="100%">Maso, Gianpaolo</style></author><author><style face="normal" font="default" size="100%">Ricci, Giuseppe</style></author><author><style face="normal" font="default" size="100%">Alberico, Salvatore</style></author><author><style face="normal" font="default" size="100%">Borelli, Massimo</style></author><author><style face="normal" font="default" size="100%">Guaschino, Secondo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of uterine fundal pressure (Kristeller maneuver) on pelvic floor function after vaginal delivery.</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Gynecol Obstet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Arch. Gynecol. Obstet.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Delivery, Obstetric</style></keyword><keyword><style  face="normal" font="default" size="100%">Dyspareunia</style></keyword><keyword><style  face="normal" font="default" size="100%">Dystocia</style></keyword><keyword><style  face="normal" font="default" size="100%">Episiotomy</style></keyword><keyword><style  face="normal" font="default" size="100%">Fatigue</style></keyword><keyword><style  face="normal" font="default" size="100%">Fecal Incontinence</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Fetal Distress</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Labor Stage, Second</style></keyword><keyword><style  face="normal" font="default" size="100%">Pain, Postoperative</style></keyword><keyword><style  face="normal" font="default" size="100%">Pelvic Floor</style></keyword><keyword><style  face="normal" font="default" size="100%">Pelvic Organ Prolapse</style></keyword><keyword><style  face="normal" font="default" size="100%">Perineum</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style  face="normal" font="default" size="100%">Pressure</style></keyword><keyword><style  face="normal" font="default" size="100%">Puerperal Disorders</style></keyword><keyword><style  face="normal" font="default" size="100%">Urinary Incontinence</style></keyword><keyword><style  face="normal" font="default" size="100%">Uterus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">286</style></volume><pages><style face="normal" font="default" size="100%">1135-9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;PURPOSE: &lt;/b&gt;To evaluate the role of uterine fundal pressure during the second stage of labor (Kristeller maneuver) on pelvic floor dysfunction (urinary and anal incontinence, genital prolapse, pelvic floor strength).&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;522 primiparous women, enrolled 3 months after vaginal delivery, were divided in two groups: group A (297 women) identifies the women who received Kristeller maneuvers with different indications (e.g. fetal distress, failure to progress, mother exhaustion), group B (225 women) the women without maneuver. Participants were questioned about urogynecological symptoms and examined by Q-tip test, digital test, vaginal perineometry and uroflowmetric stop test score.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Mediolateral episiotomies, dyspareunia and perineal pain were significantly higher in Kristeller group, whereas urinary and anal incontinence, genital prolapse and pelvic floor strength were not significantly different between the groups.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Kristeller maneuver does not modify puerperal pelvic floor function but increases the rate of episiotomies.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/22752555?dopt=Abstract</style></custom1></record></records></xml>